Headlines about Atossa Genetics (NASDAQ:ATOS) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.1166991639383 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Atossa Genetics (NASDAQ ATOS) remained flat at $0.35 during midday trading on Thursday. 180,489 shares of the company’s stock were exchanged. Atossa Genetics has a 12-month low of $0.32 and a 12-month high of $4.20. The company has a 50-day moving average of $0.45 and a 200 day moving average of $0.87. The stock’s market capitalization is $2.99 million.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/03/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-atossa-genetics-nasdaqatos-stock-price.html.

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.